A major study published by Washington University School of Medicine in St. Louis, analyzing data from more than 600,000 people through US Department of Veterans Affairs databases, has found that GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may be effective at treating and preventing substance use disorders across every major addictive substance studied. The findings, described by researchers as one of the most significant addiction-related discoveries in years, suggest that the drugs originally developed for diabetes and weight loss could fundamentally change how addiction is treated worldwide.
For patients who already had pre-existing substance use disorders, the study found that GLP-1 drugs were associated with 50 percent fewer substance-related deaths, 39 percent fewer drug overdoses, and 26 percent fewer drug-related hospitalizations. Among people without prior substance use disorders, the medications reduced the risk of developing new addiction by 25 percent for opioids, 20 percent for cocaine, 20 percent for nicotine, 18 percent for alcohol, and 14 percent for cannabis. The breadth of the findings across multiple substances was particularly striking, as most addiction treatments target only one specific substance.
Researchers believe the mechanism involves what they describe as silencing drug noise, the relentless craving that drives addiction across substances. GLP-1 drugs appear to act on reward pathways in the brain, reducing the biological compulsion to seek out addictive substances without causing adverse effects. In supporting animal studies, vervet monkeys given semaglutide drank significantly less alcohol, not because the drug made them ill but because alcohol appeared to lose its appeal entirely. The finding aligns with growing anecdotal reports from patients on GLP-1 medications who have described losing interest in alcohol, smoking, and compulsive behaviors.
In a separate but related discovery published in Nature Communications, researchers from the University of Bristol and University College London found that GLP-1 drugs may also protect the heart after heart attacks by opening microscopic blood vessels that remain blocked even after emergency treatment. The study found that the medications could reduce complications in up to half of heart attack patients, adding cardiovascular protection to the growing list of benefits beyond weight loss and diabetes management. The dual findings have intensified calls from the medical community for expanded clinical trials and broader insurance coverage of GLP-1 medications.
Despite the promising results, researchers cautioned that the drugs are not yet ready to be prescribed specifically for addiction treatment. It remains unknown whether cravings return when patients stop taking the medications, and the high cost of GLP-1 drugs, which can exceed 1,000 dollars per month without insurance, presents a significant barrier to widespread adoption. The study's authors emphasized that randomized controlled trials are needed before clinical guidelines can be updated. The research comes at a critical time as the United States continues to face an opioid crisis that killed more than 81,000 Americans in 2025, and global substance use disorders affect an estimated 35 million people according to the World Health Organization.
Comments